HW252001

HW252001 is an investigational small molecule inhibitor developed by the Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. for the treatment of idiopathic pulmonary fibrosis (IPF). It functions as a selective inhibitor of Rho-associated protein kinase 2 (ROCK2), a signaling protein that plays a pivotal role in regulating the actin cytoskeleton and mediating fibrotic responses. By targeting ROCK2, HW252001 aims to inhibit the activation and differentiation of myofibroblasts, thereby reducing the excessive deposition of extracellular matrix proteins that characterize lung scarring in IPF. The drug is currently in Phase I clinical development, with studies focused on evaluating its safety, tolerability, and pharmacokinetic profile in healthy volunteers before proceeding to patient populations.